Skip to content
Medical Health Aged Care, Research Development

Australian Practitioners Set to Benefit from Global Announcement Shaping the Future of 3D Dental Diagnostics

Eyes of AI 2 mins read

Eyes of AI™, a global leader in AI-powered dental imaging, has announced a partnership with W&H, a world-renowned manufacturer of medical technology products and a pioneer in advanced dental equipment.

This partnership marks a major leap forward in AI-driven dental imaging, bringing together Eyes of AI’s state-of-the-art AI segmentation technology with W&H Group’s high-precision imaging equipment. 

Designed with the needs of modern dental practices in mind, the solution combines EAI’s advanced segmentation technology with W&H Group’s leading products to deliver a world-first in dental imaging.

The platform offers real-time visualisation of the mandibular canal and high-resolution 3D mapping of pulp chambers and root canal systems — dramatically improving diagnostic accuracy and treatment planning. It also streamlines workflows with features like automatic nerve tracing, 3D volume alignment, arch line generation, and precise teeth segmentation, offering dentists unprecedented visual clarity and efficiency.

Advanced spatial modelling helps dental practitioners to place implants, perform root canal treatment and remove impacted teeth with precision while patient engagement is enhanced through interactive 3D visualisations, transforming patient consultations and enabling practitioners to demonstrate procedures, treatment options and expected outcomes.

Khoa Le, Co-founder and Chief Executive of Eyes of AI™ said, “The collaboration represents a significant milestone in medical imaging innovation.”

“By combining our AI segmentation technology with the W&H Group’s advanced software, we’re enabling dental professionals to achieve superior patient outcomes through precise diagnostics and treatment planning,” said Khoa.

“Our vision has always been to make a profound difference in the lives of people worldwide and partnering with the W&H Group, an organisation with significant global reach, enables us to do that,” he added.

Valeria Ferrari, Portfolio Director at W&H said, “The future of dental imaging lies in the seamless fusion of advanced hardware and intelligent software. By choosing Eyes of AI, we’re empowering dental professionals with unprecedented clarity and precision in their daily practice.”

W&H will be demonstrating Seethrough at EuroPerio 2025 in Vienna, Austria from 14h - 17th May 2025. 

 


About us:

For more information about Eyes of AI, visit their website here: https://www.eyesofai.com.

For more information about the W&H Group, visit their website here: https://www.wh.com


Contact details:

For media enquiries please contact Alicia Grabowski / Project PR & Media / [email protected] / 0401878496

Media

More from this category

  • Medical Health Aged Care
  • 03/03/2026
  • 02:26
Tilray Brands, Inc.

Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027Tilray’s Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1Conference Call Scheduled for 12:30pm ETNEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly…

  • Medical Health Aged Care
  • 02/03/2026
  • 23:11
SBC Medical Group Holdings Incorporated

SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure

IRVINE, Calif.–BUSINESS WIRE– SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services…

  • Contains:
  • Medical Health Aged Care
  • 02/03/2026
  • 18:11
Takeda Pharmaceutical Company Limited

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--BUSINESS WIRE-- Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.